Study Finds Life-Threatening Risks from Medication Errors in Hospitals Treating Pulmonary Hypertension Patients

SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Pulmonary arterial hypertension (PAH) patients using infused drugs have suffered serious injury or in some cases died from medication errors in hospitals and other inpatient settings, according to a peer-reviewed study by Accredo Health Group and several university hospitals that surveyed doctors, nurses and pharmacists. The study, which was presented at the American College of Chest Physicians' annual meeting and will be published in the medical journal CHEST, examined medication errors for patients infused with epoprostenol (Flolan®) and treprostinil (Remodulin®) and provided guidelines to help reduce these risks.

Pulmonary arterial hypertension is a debilitating, life-threatening condition without a cure that can lead to heart failure and lung transplants. Epoprostenol and treprostinil inhibit the blood from clotting and also widen blood vessels to ease blood pressure in the lungs and reduce strain on the heart. The medications belong to a group called prostacyclins, which need to be continuously infused into the body for pulmonary hypertension patients to survive. The drugs are dosed in extremely small quantities and giving a patient too much or too little can lead to patient injury or death.

"Prostacyclins are the most potent drugs used to treat PAH and have a very narrow therapeutic window, making the proper use of medications paramount to keep patients safe," said Mark A. Tankersley, Ph.D., director of health outcomes solutions at Accredo Health Group, Inc. and one of the authors of the study. "These patients are in an extremely vulnerable condition - normally in the advanced stages of this debilitating condition. Our survey exposes the severity of the problem but also presents some possible solutions to address it."

An electronic survey of 97 clinicians at treating facilities found that 68 percent reported errors associated with administering prostacyclins and 28 respondents reported serious errors including nine that resulted in death. A separate telephone survey found that 17 of 18 nurses at pulmonary arterial hypertension centers reported serious medication errors, including three deaths. The results showed that medication errors included providing the wrong drug to the patient, improper dosing, incorrectly flushing the patient's catheter line and accidental stoppage of the infusion pump.

Researchers made the following recommendations: clearer record-keeping, clinician training, double-checking dosage factors (concentration, patient weight, pump rate and time), color coding cassettes for different drugs, marking line connections for drugs, proper medication storage, ensuring that the infusion pumps are working correctly, and requiring two nurses to sign-off on administering the medication.

PAH affects about 20,000 Americans and presently does not have a cure. One form of pulmonary arterial hypertension has no known cause. For other patients, it results from congenital heart disease, HIV infection, thyroid disease, and the use of certain diet medications or street drugs. The condition is often misdiagnosed in its early stages, but as the condition worsens it can lead to fainting, lightheadedness during physical activity, swelling in the legs and ankles, and bluish toned lips and skin (cyanotic).

CHEST, the official publication for the American College of Chest Physicians, will publish the article in an upcoming issue. Researchers at Accredo Health Group, The University of Texas Southwestern Medical Center at Dallas, University of California at San Diego, and University of California at San Francisco authored the study and suggested guidelines for protocols.

For more information about this study, please visit www.medcoresearch.com.

About Accredo Health
Accredo Health Group, Inc., a wholly-owned subsidiary of Medco Health Solutions, Inc., is one of the nation's largest specialty pharmacies dedicated to providing an enhanced level of personalized service to patients with chronic and complex disease. Drugs dispensed by Accredo, which are often biotechnology drugs, frequently require special handling and clinical services to ensure the drugs are properly administered to promote patient safety and health.

About Medco
Medco Health Solutions, Inc. (NYSE: MHS) is pioneering the world's most advanced pharmacy® and its clinical research and innovations are part of Medco making medicine smarter(TM) for more than 60 million members.

With more than 20,000 employees dedicated to improving patient health and reducing costs for a wide range of public and private sector clients, and 2008 revenue exceeding $51 billion, Medco ranks 45th on the Fortune 500 list and is named among the world's most innovative, most admired and most trustworthy companies.

For more information, go to http://www.medcohealth.com.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

Editor's note: All rights in the product names of all third-party products listed in this release, whether or not appearing with the trademark symbol, belong exclusively to their respective owners.